🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Interplay between gut microbial communities and metabolites modulates pan-cancer immunotherapy responses dlvr.it/TK3WlB

Featured Article: Microbiota changes with CRC tumor location Fecal microbial changes in proximal vs distal CRC w/specific microbes linked to tumor location. Multi-cohort analysis demonstrates diagnostic potential of location-specific fecal bacteria in CRC cell.com/cell-host-micr…

Nobel laureate Bill Kaelin on Killing the Science Golden Goose. "This is especially worrisome because becoming a scientist is largely taught by apprenticeship, with each generation teaching the next. We risk losing the next generation, our “seed corn”" amjmed.com/article/S0002-…

Cancer deaths are rising? No. That’s a lie. Cancer death rates have been falling for decades. Check the data. Better science. Better treatment. Better outcomes. Fear sells. But facts matter.

Get ready to rock out! The CheckPoints will perform on June 1 at Buddy Guy’s Legends. Space is limited so secure your VIP tickets now! Proceeds benefit the next generation of cancer immunotherapy experts through SITC’s Forward Fund. sitcancer.org/funding/the-ch…

At #AACR25, stop by medical oncology fellow Stefanie Gerstberger, MD PhD's poster to learn about her study that evaluated how colibactin-producing E.coli bacteria may contribute to early-onset #colorectalcancer by damaging DNA. Memorial Sloan Kettering Cancer Center AACR Learn more: bit.ly/42NVZnJ

When the “coldest” tumors melt: Myriam Chalabi breaks new ground (again) at #AACR25. NEOASIS Trial: • 80% MPR in dMMR (70% pCR!) • 60% MPR in pMMR BOT/BAL are pushing ICB into non-immunogenic tumors. #CancerImmunotherapy #BOT/BAL

"There Is Nothing Benign About Reducing the Cancer Research Budget" jamanetwork.com/journals/jamao…

What is the cause of ADC-related ILD? Spoiler: most likely not the antibody target (e.g. not HER2). New data confirms prior observations that T-DXd affects alveolar macrophages (AM) via Fc–FcγR engagement, triggering immune activation and ultimately ILD. aacrjournals.org/cancerres/arti…

Republicans once argued that biomedical research was an engine for economic growth and helped double the NIH budget. It led to countless medical breakthroughs and saved lives. Now, they are proposing to cripple the NIH through massive cuts. Who will have the courage to say no?

.AACR establishes grant program to support early-stage and mid-career cancer researchers cancerletter.com/funding-opport…

We're excited to share that Dr. Andy Minn will return to MSK as the inaugural Chair of MSK’s new Immuno-Oncology Program in August. This is a full-circle moment for Dr. Minn, a renowned physician-scientist, who completed his postdoctoral training with Dr. Joan Massagué,

I don't understand how someone can read this and not think that the American biomedical research system is a modern miracle that should be protected at all costs

Microbiome metabolism of dietary phytochemicals controls the anticancer activity of PI3K inhibitors cell.com/cell/fulltext/… Cell Asael Roichman

The CheckPoints are ready to party - join us tonight Sunday June 1 at Buddy Guys! Best party of #ASCO25 & all for the great cause of the Society for Immunotherapy of Cancer Forward Fund that supports post-doc & trainee awards. See you tonight!!!

When patients ask what can I do to improve my shot at survival… I say we have no great evidence about diet, BUT we know that active fit cancer patients do better. NOW we have evidence that exercise itself can have a survival benefit! #keepexercisin’

Hey #ASCO25, #TheCheckPoints are thrilled to have you on our dance floor tonight in Chicago! 💃 Thanks for showing up and making it a party. For those of you missing the gig BuddyGuysLegends, here’s our cover of Bruno Mars Uptown Funk! 🎶 Russell Pachynski Jason Luke, MD, FACP Rachel Humphrey

Methotrexate exerts antitumor immune activity by inducing cGAMP generation in cancer cells and concurrently inhibiting its hydrolysis mediated by ENPP1 Science Translational Medicine science.org/doi/10.1126/sc…

I wrote a new piece on how much progress has been made in treating childhood leukemia. The answer is: quite a lot! Before the 1970s, fewer than 10% of children diagnosed survived 5 years after diagnosis. Now most are cured and around 85% survive that long.

Tune in to hear michael mauro of Memorial Sloan Kettering Cancer Center discuss ways that the newest formulation of nilotinib for Ph-positive CML addresses treatment adherence issues by reducing the need for fasting. Listen to the full episode here: hubs.ly/Q03rxsKL0